185 related articles for article (PubMed ID: 36264639)
1. Macrophage secretory IL-1β promotes docetaxel resistance in head and neck squamous carcinoma via SOD2/CAT-ICAM1 signaling.
Hsieh CY; Lin CC; Huang YW; Chen JH; Tsou YA; Chang LC; Fan CC; Lin CY; Chang WC
JCI Insight; 2022 Dec; 7(23):. PubMed ID: 36264639
[TBL] [Abstract][Full Text] [Related]
2. Curcumin Enhances the Efficacy of Docetaxel by Promoting Anti-Tumor Immune Response in Head and Neck Squamous Cell Carcinoma.
Sun L; Yao X; Liu J; Zhang Y; Hu J
Cancer Invest; 2023 May; 41(5):524-533. PubMed ID: 36946609
[TBL] [Abstract][Full Text] [Related]
3. Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization.
Sheng D; Ma W; Zhang R; Zhou L; Deng Q; Tu J; Chen W; Zhang F; Gao N; Dong M; Wang D; Li F; Liu Y; He X; Duan S; Zhang L; Liu T; Liu S
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35613826
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory mediators drive metastasis and drug resistance in head and neck squamous cell carcinoma.
St John MA
Laryngoscope; 2015 Mar; 125 Suppl 3():S1-11. PubMed ID: 25646683
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
[TBL] [Abstract][Full Text] [Related]
6. IL-1β Promotes Stemness of Tumor Cells by Activating Smad/ID1 Signaling Pathway.
Lu L; Wang P; Zou Y; Zha Z; Huang H; Guan M; Wu Y; Liu G
Int J Med Sci; 2020; 17(9):1257-1268. PubMed ID: 32547321
[No Abstract] [Full Text] [Related]
7. Inhibition of carbonic anhydrases IX/XII by SLC-0111 boosts cisplatin effects in hampering head and neck squamous carcinoma cell growth and invasion.
Sarnella A; Ferrara Y; Auletta L; Albanese S; Cerchia L; Alterio V; De Simone G; Supuran CT; Zannetti A
J Exp Clin Cancer Res; 2022 Apr; 41(1):122. PubMed ID: 35365193
[TBL] [Abstract][Full Text] [Related]
8. NLRP3 in tumor-associated macrophages predicts a poor prognosis and promotes tumor growth in head and neck squamous cell carcinoma.
Chen L; Wan SC; Mao L; Huang CF; Bu LL; Sun ZJ
Cancer Immunol Immunother; 2023 Jun; 72(6):1647-1660. PubMed ID: 36586012
[TBL] [Abstract][Full Text] [Related]
9. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
[TBL] [Abstract][Full Text] [Related]
10. Taxanes in the Treatment of Head and Neck Squamous Cell Carcinoma.
Hsieh CY; Lin CC; Chang WC
Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001888
[TBL] [Abstract][Full Text] [Related]
11. Metformin enhances gefitinib efficacy by interfering with interactions between tumor-associated macrophages and head and neck squamous cell carcinoma cells.
Yin X; Han S; Song C; Zou H; Wei Z; Xu W; Ran J; Tang C; Wang Y; Cai Y; Hu Q; Han W
Cell Oncol (Dordr); 2019 Aug; 42(4):459-475. PubMed ID: 31001733
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-loaded M1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer.
Zhao Y; Zheng Y; Zhu Y; Li H; Zhu H; Liu T
J Nanobiotechnology; 2022 Aug; 20(1):359. PubMed ID: 35918698
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics.
Stoehr M; Mozet C; Boehm A; Aigner A; Dietz A; Wichmann G
Cancer Chemother Pharmacol; 2014 Apr; 73(4):827-37. PubMed ID: 24562588
[TBL] [Abstract][Full Text] [Related]
15. Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer.
Reers S; Pfannerstill AC; Rades D; Maushagen R; Andratschke M; Pries R; Wollenberg B
Anticancer Res; 2013 Jun; 33(6):2481-9. PubMed ID: 23749899
[TBL] [Abstract][Full Text] [Related]
16. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.
O'Keefe RA; Bhola NE; Lee DS; Johnson DE; Grandis JR
PLoS One; 2020; 15(1):e0227261. PubMed ID: 31914141
[TBL] [Abstract][Full Text] [Related]
18. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation.
Noman ASM; Parag RR; Rashid MI; Islam S; Rahman MZ; Chowdhury AA; Sultana A; Jerin C; Siddiqua A; Rahman L; Nayeem J; Akther S; Baidya S; Shil RK; Rahman M; Shirin A; Mahmud R; Hossain SMI; Sumi SA; Chowdhury A; Basher SB; Hasan A; Bithy S; Aklima J; Chowdhury N; Hasan MN; Banu T; Chowdhury S; Hossain MM; Yeger H; Farhat WA; Islam SS
Cell Death Dis; 2020 Aug; 11(8):663. PubMed ID: 32814771
[TBL] [Abstract][Full Text] [Related]
20. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
